Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Glioma 2 Glioblastoma 2 Recurrence 1 Papillomavirus Infections 1 Medulloblastoma 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Human Papillomavirus-Related Cervical Carcinoma 1 Astrocytoma 1 Advanced Fallopian Tube Carcinoma 1

Interventions

human papillomavirus vaccine, L1 type 16, 18 40 Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 32 Papillomavirus Vaccines 24 Human Papillomavirus Recombinant Vaccine nonavalent 12 Vaccines 11 Blood Specimen Collection 10 Data Collection 9 Colposcopy 9 Human Papillomavirus DNA Tests 8 Specimen Handling 7 Radiotherapy, Intensity-Modulated 7 Cisplatin 7 Surveys and Questionnaires 6 Educational Status 6 Early Intervention, Educational 6 Carboplatin 6 Vaginal Smears 5 Vaccines, Synthetic 5 Methods 5 Engerix-B 4 fludarabine 3 epigallocatechin gallate 3 artesunic acid 3 artemisinin 3 Watchful Waiting 3 Polymerase Chain Reaction 3 Patient Navigation 3 Paclitaxel 3 Observation 3 Mass Screening 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Papillomavirus Infections × Diphtheria Toxoid × Clear all

NCT03180034 2025-09-04

ESCUDDO

National Cancer Institute (NCI)

Phase 4 Active not recruiting

27,945 enrolled

Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon ⚡